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Abstract
Aim: To describe the incidence of extensive drug-resistant tuberculosis (XDR-TB) reported in the Peruvian National
multidrug-resistant tuberculosis (MDR-TB) registry over a period of more than ten years and present the treatment
outcomes for a cohort of these patients.
Methods: From the Peruvian MDR-TB registry we extracted all entries that were approved for second-line anti-TB treatment
between January 1997 and June of 2007 and that had Drug Susceptibility Test (DST) results indicating resistance to both
rifampicin and isoniazid (i.e. MDR-TB) in addition to results for at least one fluoroquinolone and one second-line injectable
(amikacin, capreomycin and kanamycin).
Results: Of 1,989 confirmed MDR-TB cases with second-line DSTs, 119(6.0%) XDR-TB cases were detected between January
1997 and June of 2007. Lima and its metropolitan area account for 91% of cases, a distribution statistically similar to that of
MDR-TB. A total of 43 XDR-TB cases were included in the cohort analysis, 37 of them received ITR. Of these, 17(46%) were
cured, 8(22%) died and 11(30%) either failed or defaulted treatment. Of the 14 XDR-TB patients diagnosed as such before
ITR treatment initiation, 10 (71%) were cured and the median conversion time was 2 months.
Conclusion: In the Peruvian context, with long experience in treating MDR-TB and low HIV burden, although the overall
cure rate was poor, a large proportion of XDR-TB patients can be cured if DST to second-line drugs is performed early and
treatment is delivered according to the WHO Guidelines.
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Introduction
Extensively drug-resistant tuberculosis (XDR-TB) is defined as a
disease caused by Mycobacterium tuberculosis isolates resistant to at
least isoniazid and rifampicin (which is the definition of multidrug-
resistant tuberculosis, MDR-TB) plus to at least one fluoroquin-
olone and one second-line injectable (capreomycin, kanamycin or
amikacin) [1]. XDR-TB was first introduced as a term in the
medical literature in 2006 by a survey of second-line anti-TB drug
resistance among MDR-TB isolates collected worldwide [2]. The
same year, the international community was alarmed by the report
of an outbreak of XDR-TB in the South African province of
KwaZulu Natal associated to 98% lethality and short survival time
[3]. Since then, XDR-TB has been reported by several studies
[4,5,6,7] and detected in 46 countries worldwide [8]
Diagnosing XDR-TB is very challenging as it requires capacity
to perform Drug Susceptibility Tests (DSTs) for fluoroquinolones
and second-line injectables in addition to first-line anti-TB drugs.
In Peru, such testing has been performed since 2005 at the
National Reference Laboratory of the Instituto Nacional de Salud
(INS). Earlier, DSTs for first-line anti-TB drugs were done
nationwide in a quality-assured manner, and second-line anti-TB
drugs could only be tested in limited quantity at the Massachusetts
State Laboratory Institute (MSLI) in the United States, as part of
an international collaboration to implement the so-called DOTS-
Plus project [9,10,11].
In addition to diagnosis,treatment for XDR-TB presents an even
larger challenge due to the limitations in designing treatment
regimens. Treatment outcomes of XDR-TB patients vary between
different programmes and regions of the world with 30% cure rates
among the XDR-TB cases diagnosed in Latvia between 2000 and
2002 [1] compared to 98% mortality among those reported in the
KwaZulu Natal outbreak [3]. The very high HIV prevalence in this
area of the world [12] could explain the high mortality as HIV is
known to worsen TB and MDR-TB treatment outcomes [13].
The burden of XDR-TB and its treatment outcomes have not
yet been reported for Peru, a country where second-line anti-TB
drugs have been administered (via standardized, empiric or
individualized treatment regimens) through the National TB
control Programme (NTP) for more than ten years [9]. Like
PLoS ONE | www.plosone.org 1 August 2008 | Volume 3 | Issue 8 | e2957Latvia, Peru has a relatively low burden of HIV compared to
South Africa [12] and thus provides a different public health
context for the emergence of XDR-TB.
The aim of this study is to contribute to the growing knowledge
on XDR-TB epidemiology and management by describing the
incidence of XDR-TB cases reported in the Peruvian National
MDR-TB registry over a period of more than ten years (January
1997 to June of 2007) and to present the treatment outcomes for a
cohort of these patients.
Methods
Study population
The selection criteria for which patients receive treatment with
second-line drugs through the NTP in Peru has been changing
over the last decade [9] and have been recently standardized in the
2005 NTP guidelines [11]. At the moment patients suspected of
having MDR-TB are evaluated by either the national or the
regional expert committees (CER) to be approved for second-line
anti-TB treatment if they fulfil any of the following criteria:
persistent culture-positive results at the fourth month of therapy
with first-line drugs; documented household contact of a
confirmed MDR-TB case; or MDR-TB diagnosed through
DST. For cases waiting for DST results, these committees approve
standardized or empirical treatment regimens (STR and ETR
respectively), depending on whether the resistance pattern of the
source case is known. (STR is composed of: 4KCxEtEZ/
14CxEtEZ where K=kanamycin, Cx=ciprofloxacin, Et=ethio-
namide, E=ethambutol, Z=pyrazinamide). A sputum sample is
then collected for smear, culture and DST. Regional laboratories
perform initial first-line DSTs and, as of March of 2005, culture
positive samples are sent to the INS where DSTs are performed
for first and second-line drugs. DST results are used by the CER to
tailor the individualized treatment regimen (ITR) [11,14]. Prior to
the publication of the Peruvian official treatment guidelines for
MDR-TB in 2005 [15], second-line DST results were done
through the MSLI, though this was not the general practice.
The CER tailors ITR for MDR-TB and XDR-TB cases
generally based on the available DST results. Regimens consist of
at least five different drugs to which the patient is susceptible, with
first line drugs utilized when possible. Cases that are suspected of,
or the DST shows resistance to ciprofloxacin are generally given
moxifloxacin (in rare occasion, gatifloxacin was used). Injectable
drugs are administered daily and indicated in order of efficacy
depending, on resistance: streptomycin, kanamycin and capreo-
mycin. Second line bacteriostatics (ethionamide, cicloserine and P-
aminosalicylic acid) are then added to complete the regimen.
Further details on treatment regimens and the clinical care
practices used for MDR-TB patients are described in detail
elsewhere [16,17].
All patients approved for treatment with second-line anti-TB
drugs through the NTP are routinely recorded in a National
MDR-TB Registry.
For the purpose of this study we extracted all entries in the
registry dated between January1997 and June of 2007 and that
had DST results indicating MDR-TB. From this group of
confirmed MDR-TB cases, we selected all cases that had a DST
performed for at least one fluoroquinolone and one second-line
injectable at any moment before or during treatment.
Cohort
For the outcome and culture conversion analyses, we considered
the cohort of DST-confirmed MDR patients that began an ITR
before March of 2005, when the new national guidelines for
MDR-TB treatment [15] where published. We included only
patients that had DST results for at least rifampicin, isoniazid, one
fluoroquinolone and one second-line injectable (hence being able
to confirm or reject XDR-TB diagnosis)[18].
Definitions and statistical analysis
Internationally recommended definitions of treatment outcomes
were used for the analysis [19]. In the case of multiple outcomes,
we choose the first outcome assigned to the patient (as indicated by
the World Health Organization (WHO) [20]). Similarly, to define
culture conversion we used the consensus definition of two
consecutive negative cultures collected at least 30 days apart
[19,21]. A positive culture after conversion was considered
reversion [21]. In this study, we focused on ‘‘final conversion’’,
or the point at which the culture becomes negative and does not
show a positive result again.
XDR-TB cases were compared to the MDR-TB cases who were
also confirmed as not having XDR-TB (‘‘MDR group’’), meaning
that they were shown to not be resistant to any fluoroquinolone or
second-line injectable.
In an attempt to capture differences that may result from having
more information on resistance before or after starting treatment,
both groups (MDR and XDR-TB) were stratified according to the
date of the DST that confirmed or excluded XDR-TB diagnosis.
Detailed description of the composition of the strata is presented in
Table 1.
Comparisons of outcomes between XDR-TB and MDR-TB,
and between the different strata was done using Pearson’s Chi-
squared tests. Dichotomous outcomes and associated odds ratios
were computed using Fisher’s exact method. Culture conversion
was described using Kaplan-Meier graphs and compared with the
Log-Rank Test. When constructing conversion curves, individuals
Table 1. Stratification of cases according to the date of the DST and the detection of XDR-TB.
MDR-TB XDR-TB
Stratum 1 Lab confirmed MDR-TB with 2
nd-line DSTs for at least a FQ and
an INJ, dated BEFORE or up to 31 days after treatment initiation.
Lab-confirmed XDR-TB cases, from DSTs dated BEFORE or up to 31 days
after treatment initiation.
Stratum 2 Lab confirmed MDR-TB with 2
nd-line DSTs for at least a FQ and
an INJ, dated .31 days AFTER treatment initiation.
Lab-confirmed XDR-TB cases from DSTs dated .31 days AFTER
treatment initiation, without previous DSTs that include 1 FQ and 1 INJ
Stratum 3
1 Lab-confirmed XDR-TB cases from DSTs dated .31 days after treatment,
with previous DSTs that include 1 FQ and 1 INJ, but hadn’t shown to be
XDR
1Patients diagnosed with XDR-TB later than 31 days after treatment initiation are subdivided into strata 2 and 3 to differentiate patients with documented amplification
of resistance (strata 3) to patients without enough DST information to document amplification towards XDR-TB, or XDR-TB at the start of treatment.
doi:10.1371/journal.pone.0002957.t001
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or if conversion did not occur before the end of the 30-month
follow-up period, thus cases that default from treatment were
censored only if they defaulted before 30 months of treatment. In
the analysis of treatment times, Kaplan-Meier curves were also
used and considered as censored all cases that did not cure at the
end of treatment. Power and sample size calculations for Fisher’s
exact tests were computed through simulations and reported as
estimates with associated confidence intervals. Data analyses were
done using SAS version 9.0 (The SAS Institute, North Carolina,
USA), and all simulations to estimate power of tests were
performed in R version 2.5.1 (Free Software Foundation Inc.,
Massachusetts, USA). All p-values reported here are two-sided,
and significance levels were set to 0.05.
Results
A total of 7,191 cases were approved for second-line treatment
between January 1997 and June of 2007. Among them, 5,335 had
a diagnosis of MDR-TB confirmed through DST. Of these, 1,989
(37.3%) also had DST results for at least one fluoroquinolone and
one second-line injectable (second-line DST). A total of 119 XDR-
TB cases were recorded in the National MDR-TB registry in the
study period, which represent 2.2% of all DST-confirmed MDR-
TB cases and 6?0% of the MDR-TB cases who had DST results
for at least one fluoroquinolone and one second-line injectable in
addition to first-line drugs. Forty-two of the 119 (35.3%) XDR-TB
cases were tested for HIV and no cases of XDR-TB/HIV co-
infection were detected.
The distribution of XDR-TB between sex and age groups did
not differ significantly from that of MDR-TB (Table 2). Over 90%
of XDR-TB cases were found to live in Lima and its metropolitan
area, which follows the distribution of MDR-TB in the country
(P=0.2998).
History of previous anti-TB treatment
Results of the analyses of history of previous anti-TB treatment
are shown in Table 3. Cases with XDR-TB had a greater number
of previous treatments than those with MDR-TB (2.0 and 1.6
respectively, P=0.0026). Specifically, the XDR group had a
significantly higher proportion of patients that underwent two or
more previous treatments compared to the MDR group. Among
XDR-TB cases 11.5% (95% C.I.=5.6–17.4) had never been
treated before, similarly to what found in the MDR group (11.1%,
95% C.I.=(9.6–12.5)) (P=0.8774). The proportion of XDR-TB
cases never treated with second-line anti-TB drugs (40.5%, 95%
C.I=31.4–49.7) was significantly lower than in the MDR group
(63.3%, 95 % C.I=(61.1–65.6)) (P,0.0001).
Treatment outcome analysis
Five of the 119 XDR-TB cases (4.2%) and 40 of the 1,870
MDR-TB cases (2.1%) were excluded from the cohort group used
for the outcome analysis because the second-line DST results were
dated more than two months after treatment completion. Sixty-
one XDR-TB and 732 MDR-TB cases were approved for second-
line treatment before March of 2005 (the cut-off date). One XDR-
TB patient (1.6%) died before starting treatment, while 22 patients
with MDR-TB (2.9%) were approved for second-line treatment
but did not start, eight due to death. Four and 24 XDR-TB and
MDR-TB patients, respectively, were excluded because they
started treatment after the cut-off date. Finally, 38 of the
remaining 686 MDR-TB patients and 13 of the 56 XDR cases
were excluded from the outcomes analysis because they were still
in treatment. Therefore the cohort analyzed for treatment
outcomes consisted of 43 XDR-TB cases (37 on ITR and 6 on
STR), and 648 MDR-TB cases (494 on ITR and 154 on STR).
Table 4 shows the treatment outcomes of XDR-TB and MDR-
TB patients. Overall, 42% of XDR-TB cases were cured.
Treatment outcomes were significantly different between patients
who underwent STR and ITR (P=0.0380). Though the
proportion of cured patients was higher among those who
underwent ITR, the difference was not statistically significant
(P=0.3747).
The cure rate of XDR-TB patients who underwent ITR was
45.9% compared to 69.2% of those with MDR-TB (OR=0.38,
95% C.I.=0.18–0.78). Treatment failures and deaths were
significantly higher in the XDR group (OR=1.38, 95%
C.I=0.51–3.72 and OR=3.2, 95% C.I.=1.2–7.8, respectively).
Distribution of outcomes was not significantly different
(P=0.9999) between MDR-TB and XDR-TB patients who
underwent ITR with a second-line DST dated before or up to
31 days after treatment initiation (stratum 1). In this stratum,
71.4% (10/14) of XDR-TB cases were cured, compared to 68.9%
of those with MDR-TB (241/334; OR=0.96, 95% C.I.=0.30–
3.15). In the same stratum, the proportion of patients who failed or
died was statistically similar for MDR and XDR groups
(P=0.3888 and 0.3873 respectively).
Table 4 shows that the distribution of outcomes for the XDR
group was not significantly different between strata 2 and 3
Table 2. Comparison of age, sex and geographic distribution
between XDR and MDR.
XDR MDR P-value
(n=119) (n=1870)
Sex
Male 58.8%(70) 59.7%(1116) 0.7727
Female 41.2%(49) 40.3%(754)
Age
Median 27.0 27.0 0.3126
Range (10–78) (0–82)
Geographic Distn.
Lima-Callao 90.8%(108) 87.5%(1637) 0.2998
Province 9.2%(11) 12.5%(233)
doi:10.1371/journal.pone.0002957.t002
Table 3. History of prior treatments and number of never
treated cases for XDR-TB compared to MDR-TB.
XDR-TB MDR-TB P-value
Pervious treatments (1
st+2
nd line) N=113 N=1755
Never treated (NT) 12%(13) 11%(194)
1 treatment 24%(27) 40%(693)
2 treatments 33%(37) 29%(503) 0.0039
.2 treatments 32%(36) 21/%(365)
NT with first-line regimen 15%(17) 14%(241)
* 0.7115
NT with second-line regimen 41%(45)
{ 63%(1061)
{ ,0.0001
*N=1746.
{N=111.
{N=1676.
doi:10.1371/journal.pone.0002957.t003
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strata of MDR-TB patients, only stratum 3 showed a significantly
lower percentage of cured XDR-TB cases compared to MDR-TB
(OR=0.10, 95% C.I.=0.01–0.83). The percentage of cured
patients in stratum 2 of XDR-TB cases was 37.5% (6/16), which
is not significantly lower than that found in the MDR-TB group
(OR=0.35; 95% C.I.=0.12–1.01).
Duration of treatment
In the cohort of patients under ITR, XDR-TB patients received
treatment for a significantly longer duration. The median time to
cure for XDR-TB patients was 43.1 months, compared to the
average 28.5 months that MDR-TB cases spent in treatment
(P,0.0005).
For stratum 1, XDR-TB cases were cured in a median of 27.7
months compared to 24.9 months for MDR-TB (P=0.1790). In
the higher strata, MDR-TB patients were cured on average 2
months earlier than the XDR-TB group (P=0.0063).
Culture Conversion analysis
Overall, culture conversion in the MDR group occurred at a
median of three months compared to that of 26 months in the
XDR-TB cohort (P=0.0006). The stratified analysis suggests that
the date of the DST is also associated with culture conversion.
Figure 1 shows the Kaplan-Meier graph of the probability of
conversion by month of treatment.
As shown in Figure 1, culture conversion was found to follow a
similar path for MDR-TB and XDR-TB cases in stratum 1, with
half of the cases reaching culture conversion by the second month
in treatment and roughly 75% by the sixth month (P,0.3885).
Culture conversion was significantly slower in the higher strata,
though the difference was more pronounced in the XDR group.
Among patients with DST dated more than 31 days after starting
treatment (strata 2 and 3), culture conversion occurred signifi-
cantly quicker in the MDR group (P=0.0220). For both XDR
strata with DST after treatment initiation the proportion of
patients reaching culture conversion in the first 30 months of
treatment was below 50%.
Discussion
Patients with XDR-TB represent 6.0% of all laboratory-
confirmed MDR-TB cases recorded in the Peruvian MDR-TB
registry between January 1997 and June of 2007 who had DST
results for first-line drugs and for at least one fluoroquinolone and
one second-line injectable. In contrast to findings from Latvia
where XDR-TB cases are spread countrywide [2], the vast
majority of cases in Peru have been found in Lima and its
surrounding areas. This distribution follows the geographic spread
of MDR-TB in Peru for this period, where 87% of cases occur in
the capital and its surrounding areas. Although the overall cure
rate was significantly lower in XDR-TB than in MDR-TB, the
timing of the DST result was significantly associated with an
improvement in the treatment outcomes and the time to culture
conversion. In fact, our study shows that ten of the fourteen XDR-
TB cases (71%) with a DST result dated before or 31 days after
starting treatment were cured under ITR. These results surpass
those reported in Latvia where 61% of the XDR-TB cases
experienced a favourable outcome, though less strict criteria were
used to define XDR-TB (i.e. MDR-TB plus resistance to 3 or
more of the 6 classes of second-line drugs) [2]. Our findings are in
line with the outcome analysis of a group of XDR-TB cases from
New York City [22] where XDR-TB diagnosed prior to starting
treatment had better outcomes compared to those who acquired
XDR-TB during treatment.
Looking at treatment history, 11.5% XDR-TB cases had never
been treated with any anti-TB drugs and 40.5% had never been
treated with second-line drugs. This information provides a rough
estimate of the proportion of primary XDR-TB in Peru but
Table 4. Outcome results for all XDR cases by treatment regimen.
N Cure (%)
Treatment
Completed (%) Death (%) Failed (%) Default (%) P-value (%)
XDR
STR 6 1(17) 2(33) 0(0) 1(17) 2(33)
ITR 37 17(46) 1(3) 8(22) 5(14) 6(16)
Total 43 18(42) 3(7) 8(19) 6(14) 8(19) 0.0380
XDR vs. MDR (ITR Only)
XDR 37 17(46) 1(3) 8(22) 5(14) 6(16)
MDR 494 342(69) 30(6) 39(8) 50(10) 33(7) 0.0044
Stratum 1
XDR 14 10(71) 1(7) 1(7) 1(7) 1(7)
MDR 334 241(72) 23(7) 26(8) 22(7) 22(7) 0.9999
Stratum 2
XDR 16 6(38) 0(0) 5(31) 2(13) 3(19)
MDR 160 101(63) 7(4) 13(9) 28(17) 11(11)
Stratum 3
XDR 7 1(14) 0(0) 2(29) 2(29) 2(29) 0.0130
Comparison of outcomes for XDR vs. MDR patients under the Individualized Treatment Regimen (ITR), stratified according to timing of Drug Sensitivity Test (DST). Includes
cases who finished treatment; 13/56 (23%) XDR and 30/524 (5.7%) MDR were still on treatment.
Stratum 1: 2nd-line DST result dated prior to, or up to 31 days after treatment initiation; Stratum 2: 2nd-line DST result dated more than 31 days after treatment
initiation; Stratum 3 (only XDR cases): 2nd-line DST result diagnosing XDR-TB, dated more than 31 days after with previous DSTs not having XDR-TB resistance pattern.
doi:10.1371/journal.pone.0002957.t004
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estimate the proportion of cases who acquired XDR-TB during
treatment. Nonetheless, this analysis for XDR-TB cases points out
an important distinction. Under programmatic conditions,
primary MDR-TB cases are defined as those that were diagnosed
through a DST performed before beginning the very first anti-TB
treatment (i.e. cases that were never treated before). In the context
of XDR-TB however, the concept of primary resistance becomes
more complex. While XDR-TB cases that were never treated
before can be labelled as primary cases, we consider that
monitoring the number of XDR-TB cases that have never been
exposed to second-line drugs (particularly fluoroquinolones or
second-line injectables) is equally important, and fit a more
nuanced category of ‘probable primary’ resistance.
In our study, XDR-TB patients generally had less favourable
outcomes and longer times to culture conversion than those with
MDR-TB, which is evidence to the greater challenge of treating
and controlling XDR-TB. However, a more careful evaluation
suggests that XDR-TB cases can have similar outcomes to their
MDR counterparts; when the DST was done close to treatment
initiation, 71% of XDR-TB cases were cured, compared to 72%
for MDR-TB patients. The results of the stratified analysis support
the idea that having first- and second-line DST performed prior to
treatment initiation can considerably improve the chances of cure,
even for XDR-TB, provided the WHO treatment guidelines are
followed [20] . Early DST can also result in quicker culture
conversion, reducing the infectious period and disease transmis-
sion, even in the case of XDR-TB. DST results will in fact inform
the composition of an ITR which, delivered under DOT, will
allow use of effective drugs against the bacillus with consequent
treatment of the disease and control of the amplification of
resistance during treatment [23,24].
Though the NTP suggests ending treatment at the 24th month,
it is common that treatment be prolonged beyond this period,
especially in patients that are persistently culture-positive.
Consequently, programmatic outcomes (i.e. outcomes assigned
by the CER and recorded in the registry) do not always match the
outcomes following the consensus definitions [19]. In our study,
this happened for 3 XDR-TB cases. All three failed by
programmatic standards but did not have the culture information
to assign a consensus definition. Disparities between programmatic
and consensus definitions were greater in the MDR group where
87% of 30 cases labelled treatment completers were cured by
programmatic standards. Hence, difference in cure rates for
MDR-TB and XDR-TB would be more pronounced under
programmatic standards.
A limitation of this study is the small sample size of the XDR-
TB cohort, which affects the power of statistical tests, as well as the
reliability of estimates of conversion time and cure rates. For
example, although no significant difference was detected when
comparing the proportion of cures of XDR-TB patients who
underwent STR and ITR. However, due to the small sample size,
the chances of detecting any difference if there was one, was
estimated between13.9% and 15.2%. Similarly, the second strata
of the XDR group showed no significant difference in the
proportion of patients cured compared to the MDR counterparts,
Figure 1
doi:10.1371/journal.pone.0002957.g001
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was approximately 20%. In both cases, the estimated power of the
analysis was well below the usually recommended value of 80%.
The cohort analysis of XDR-TB patients reveals better
treatment outcomes compared to previous reports [1,3]. The
striking difference in outcomes compared to the report from South
Africa could be explained in part by the different levels of HIV co-
infection. It is unknown whether treatment outcomes of XDR-TB
treatment programmes in settings with relatively low HIV burden
such as Peru, can be reproduced in areas with high HIV
prevalence. However, our data show that in the absence of HIV,
XDR-TB is a treatable disease.
In Peru, HIV prevalence is relatively low [12] and this is
reflected in this study by the fact that no cases of XDR-TB/HIV
were detected. However, two potential confounders could cause an
underestimation of XDR-TB/HIV co-infection. First, the cover-
age of HIV testing among MDR-TB patients was extremely low
before 2005, when policy was implemented recommending HIV
testing for all patients approved for treatment with second-line
drugs. Second, before March of 2005 patients had to fail STR
before getting a second-line DST, a circumstance where XDR/
HIV co-infected patients could have died before receiving second-
line DST.
Conclusion
Peru is a setting with a well-established TB control program,
large experience treating MDR-TB and a low HIV burden. Given
that the laboratory capacity of performing second-line DST has
greatly increased recently, it is likely that the number of notified
XDR-TB cases will also increase in the coming years. Neverthe-
less, this study presents evidence suggesting that in the Peruvian
context, a large proportion of XDR-TB patients can be cured if
DSTs for first and second-line drugs are performed early and
treatment is delivered according to the WHO Guidelines. Though
the overall cure rate was low compared to MDR-TB patients,
outcomes and time to culture conversion were significantly better
in patients who received DST close to treatment initiation when
the ITR is first tailored. Though other important factors that
influence the chances of being cured were not analyzed (e.g.
specific drugs used in treatment regimens and pulmonary surgical
intervention), our findings provide a potentially favourable
perspective for patients affected by this form of tuberculosis. This
study reinforces the importance to accelerate efforts to develop
laboratory capacity for universal access to DST to both first- and
second-line anti-TB drugs as well as to introduce rapid diagnostic
tools for MDR and XDR-TB [25].
Disclaimer: MZ and EJ are staff members of the World
Health Organization. The authors alone are responsible for the
views expressed in this publication and they do not necessarily
represent the decisions or policies of the World Health
Organization.
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